The paradigm in cardiovascular prevention is shifting, and the latest data from Amgen’s VESALIUS-CV trial solidifies Repatha’s (evolocumab) position at the forefront. This isn’t simply about lowering LDL-C; it’s about proactively reducing the risk of *first* major adverse cardiovascular events (MACE) in a high-risk population – even those without established atherosclerosis. This is a critical distinction, signaling a move away from treating disease *after* it manifests and towards preventing it in the first place. The findings, presented at the American College of Cardiology (ACC) 75th Annual Scientific Session and published in JAMA, come at a pivotal moment as new guidelines emphasize earlier, more aggressive lipid-lowering therapy.
- Repatha Demonstrates Primary Prevention Benefit: For the first time, a PCSK9 inhibitor shows a significant reduction in MACE risk in high-risk patients *before* the onset of significant arterial plaque buildup.
- LDL-C Levels Matter: Achieving LDL-C levels below 45 mg/dL with Repatha, a target often unattainable with statins alone, is linked to substantial risk reduction.
- Guideline Alignment: These results reinforce the recent ACC/AHA guideline recommendations for earlier and more intensive LDL-C lowering.
For decades, the focus of cardiovascular care has been on secondary prevention – managing risk in patients who have already experienced a heart attack or stroke. While crucial, this approach misses a significant opportunity to prevent these events altogether. VESALIUS-CV specifically targeted a high-risk primary prevention cohort – individuals with diabetes and elevated LDL-C, but without known significant atherosclerosis. The 31% reduction in the composite primary endpoint of coronary heart disease (CHD) death, myocardial infarction, or ischemic stroke is compelling. The fact that a similar reduction was seen in a broader endpoint including ischemia-driven revascularization further underscores the benefit. The median LDL-C achieved of 44 mg/dL is particularly noteworthy, as it highlights the potential of PCSK9 inhibitors to reach targets previously considered difficult to attain.
The timing of these results is no accident. The broadened FDA approval of Repatha in August 2025 to include adults at increased risk for CV events due to uncontrolled LDL-C paved the way for a more proactive approach to patient care. This approval, coupled with the updated guidelines, creates a favorable environment for increased Repatha utilization. Amgen has already seen over 8 million patients globally benefit from the drug, and this number is poised to grow.
The Forward Look
The VESALIUS-CV data will undoubtedly fuel further debate regarding the appropriate intensity of lipid-lowering therapy. Expect to see increased pressure on healthcare providers to assess and manage LDL-C levels more aggressively, particularly in high-risk primary prevention populations. The key question now is not *if* we should lower LDL-C further, but *how* to do so effectively and equitably. Cost and access to PCSK9 inhibitors remain significant barriers. We can anticipate increased scrutiny from payers and a focus on identifying patients who will derive the greatest benefit from these therapies. Furthermore, Amgen’s commitment to cardiovascular innovation, extending beyond LDL-C to address other drivers of CVD like Lp(a), suggests a continued pipeline of potentially transformative therapies. The next 12-18 months will be critical in observing how quickly these findings translate into clinical practice and impact cardiovascular event rates. The industry will also be watching for further analyses from VESALIUS-CV, particularly regarding the long-term effects of sustained LDL-C lowering below 45 mg/dL.
REFERENCES
- Martin SS, Aday AW, Allen NB, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2025151(8)le41–e660.
- Jurin I, et al. Outcomes of patients with normal LDL-cholesterol at admission for acute coronary syndromes: lower is not always better. J Cardiovasc Dev Dis. 2024;11(4):120.
- Domanski MJ, Tian X, Wu CO, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2024;76(13):1507-1516.
- Kalra DK, Ray KK, Bajaj A, et al. Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis. J Clin Lipidol. 2026.
- Shapiro MD. Prolonged and Pronounced Low-Density Lipoprotein Cholesterol Lowering: The Gift That Keeps Giving. Circulation. 2022;146(15):1120-1122.
- Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151(13):e771-e862.
- Vasan RS, Enserro DM, Xanthakis V, Beiser AS, Seshadri S. Temporal trends in the remaining lifetime risk of cardiovascular disease among middle-aged adults across 6 decades: the Framingham Study. Circulation. 2022:145(17):1324-1338.
- Tsimikas S, Marcovina S. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC Review Topic of the Week. JACC. 2022;80(9):934-946.
- Data on File. Amgen, 2025.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
